Kalaris Therapeutics (KLRS)

• Market cap: $88.1M
• 1 day: -5.61%
• 5 days: -5.42%
• 1 month: -41.34%
• 3 months: 82.56%
• 6 months: -12.94%
• Year to date: -54.49%
• 1 year: -76.91%
• 5 years: -99.34%
• 10 years: -99.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.